B of A Securities Rates Amphastar Pharmaceuticals (AMPH) sell

B of A Securities has downgraded AMPH to a sell and set a $20 price target, a 1.04% downside from the current price.

By EarningsIQ Research Desk · Published Jun 29, 2026, 8:02 AM EDT · Updated Jul 1, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

B of A Securities rated Amphastar Pharmaceuticals, Inc. ($AMPH) "sell" with a $20 price target on June 29, 2026.

Since the rating, $AMPH is down 5.3% after 1 week, down 0.6% after 1 month and up 24.9% to date (from the $20.71 close on Jun 29, 2026).

AMPH Amphastar Pharmaceuticals, Inc.

$25.87 -2.23% year to date

Daily close · Oct 16, 2026

Key Points

B of A Securities downgraded AMPH to a sell rating with a $20 price target on June 29, 2026.
B of A Securities's $20 price target implies 1.04% downside from Amphastar Pharmaceuticals, Inc.'s ($AMPH) current $20.21 share price.
Shares of AMPH traded near $21.78 on Monday as several institutional investors adjusted their positions.
Insider activity included multiple buys in early June, with analysts divided on the stock's outlook.

Get $AMPH trade alerts by text

We text you when insiders, Congress or big funds trade $AMPH. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Amphastar Pharmaceuticals, Inc. alert may contain errors. Disclosures

B of A Securities has downgraded AMPH to a sell rating, setting a price target of $20. This change was announced on June 29, 2026, by analyst Jason Gerberry. Shares of AMPH traded around $21.78 on Monday, reflecting the market's reaction to this updated outlook.

Analyst rating track record

B of A Securities vs. the S&P 500

YTD return +4.74% hypothetical

All-time return +28.26% S&P 500 +23.59%

vs. S&P 500 +4.67% ahead of the index

Hypothetical returns from B of A Securities's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in AMPH

Several institutional investors have recently adjusted their positions in AMPH. BlackRock, Inc. slightly reduced its holdings by 40,672 shares, ending with about 5.42 million shares valued at approximately $106.2 million. Dimensional Fund Advisors LP increased its stake by 228,262 shares to hold just over 2 million shares worth about $39.7 million. State Street Corp also boosted its position by 75,729 shares, totaling roughly 1.6 million shares valued at $31.5 million. Vanguard Capital Management LLC opened a new position with 1.54 million shares valued at $30.2 million. Meanwhile, TD Asset Management Inc cut its holdings by 422,008 shares, leaving it with about 1.54 million shares worth $30.2 million.

Amphastar Pharmaceuticals, Inc. Stock Down 14.4%

Shares of AMPH traded near $21.78 on Monday. With the recent analyst downgrade, the market may be assessing its future potential more cautiously. The stock has seen varied interest from major institutional investors, suggesting a mix of confidence and caution.

12-month forecast

$AMPH price target

Amphastar Pharmaceuticals, Inc. daily closes and this analyst's $20 target. Not advice.

Insider Buying and Selling at Amphastar Pharmaceuticals, Inc.

Recent insider activity at AMPH included several purchases in early June. On June 1, insiders Richard Prins, Michael Zasloff, Diane Gerst, Gayle Deflin, and David Russell Gaugh each acquired 8,143 shares. Additionally, on the same day, Richard Prins and David Russell Gaugh bought 17,365 shares each. On June 2, Lee Howard sold 769 shares at an average price of $18.45.

Analysts Set New Price Targets

B of A Securities' downgrade to a sell with a $20 target was part of a broader trend among analysts. On June 3, Barclays maintained its hold rating with a $20 target. Earlier, Wells Fargo downgraded the stock to hold with a $19 target on May 14, while Piper Sandler reiterated a hold rating with a $21 target on May 11. The consensus among analysts reflects cautious optimism, with a mean target price leaning around the $20 mark.

Bottom Line

B of A Securities' downgrade of AMPH to a sell with a $20 target highlights concerns about the company's near-term prospects. Despite this, institutional investors have shown mixed actions in their positions, signaling varied expectations. Insider buying in early June suggests some confidence from within the company, while analysts remain divided on its future performance. Investors will continue to watch AMPH as new developments unfold.